D-20133
D-20133 is an orally active Hexadecylphosphocholine analog. D-20133 can both enhance and inhibit antigen-induced histamine release. D-20133 shows antineoplastic activity against small DMBA -induced mammary carcinomas[1][2].
Product Specifications
CAS Number
146764-26-3
UNSPSC
12352005
Target
Drug Derivative; Histamine Receptor
Related Pathways
GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling; Others
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Smiles
CCCCCCCCCCCCCCCCCCOP(OCC[N+]1(CCCCC1)C)([O-])=O
Molecular Formula
C26H54NO4P
Molecular Weight
475.69
References & Citations
[1]Grosman N. Effect of the anti-neoplastic agents edelfosine (ET-18-OCH3), ilmofosine (BM 41.440) and the hexadecylphosphocholine analogues D-20133 and D-21266 on histamine release from isolated rat mast cells. Immunopharmacology. 1999 Nov;44 (3) :211-21.|[2]Stekar J, et al. Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133. Cancer Chemother Pharmacol. 1993;32 (6) :437-44.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
245086-PE 100 µL
CUEDC1 (CUE Domain Containing 1, DKFZp547L163, FLJ20739) (PE)
Sign In for Pricing
View Details 